Dr
Bayer AG
Author in the following contributions
- Targeted alpha therapy with anti-HER2 thorium-227 antibody-chelator conjugates (HER2-TTCs) in mouse xenograft models with varying levels of HER2 expression and resistance to current state-of-the-art therapies
- Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with olaparib in a BRCA2 Deficient Xenograft Model
- Targeted alpha therapy with PSMA-TTC: Preclinical activity at different dosing schedules and total antibody doses in prostate cancer xenograft models
- In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate